Evidence map›Paper›PMID 42307996›Full record

ReviewChembiochem : a European journal of chemical biology2026

Artificial Cells: Perspective on Reconstructing Biological Cells and "Out of the Box" Innovations.

Thomas Ming Swi Chang

Abstract readReview
In one paragraph

Review in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Thomas Ming Swi ChangArtificial Cells and Organs Research Centre, Departments of Physiology, Medicine and Biomedical Engineering, Faculty of Medicine & Biomedical Sciences, McGill University, Montreal, Quebec, Canada.ORCID https://orcid.org/0000-0001-6255-5050

Funding

Virage Centre of Excellence in High Technology award, McGill University Advancement Program 271810
6 · The paper itself

Abstract

The first artificial cell (Chang 1957, 1964) was in the form of artificial red blood cells (RBCs), one of the most important cells because all cells, tissues, organs, and indeed the human being need it for survival. I first reconstructed artificial RBCs in vitro. This is made of cellular dimensions with ultrathin membranes of polymer, crosslinked protein, protein-lipid, or lipid. The next step in this work is to develop this for actual use to replace RBCs in the body. This is a more complex task requiring modifying the configuration and dimensions. Instead of starting with all three functions, a bottom-up approach is used. First, one with only oxygen transport function shows promising results in clinical trials with patients. A future direction is the development of artificial cells that have all three red blood cell functions including antioxidant, oxygen, and CO

Indexed as

Artificial CellsErythrocytesCOVID-19HumansOxygenOxygenArtificialBiotechnologyCellsNanomedicineSynthetic

Identifiers

PMID42307996
PMCPMC13274688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.